Literature DB >> 10381047

Cerebral white matter lesions in primary Sjögren's syndrome: a controlled study.

T Coates1, J P Slavotinek, M Rischmueller, D Schultz, C Anderson, M Dellamelva, M R Sage, T P Gordon.   

Abstract

OBJECTIVE: To determine the prevalence of neurological and magnetic resonance imaging (MRI) abnormalities in a well defined population of unselected patients with primary Sjögren's syndrome (SS) and age and sex matched healthy patients.
METHODS: Thirty patients with SS and 29 age and sex matched controls were examined by a neurologist and subsequently underwent MRI scanning with a 1.0 Tesla Siemens Impact MR scanner. Scans were graded by a neuroradiologist blinded to the clinical status of each subject. The number and location of white matter lesions > 3 mm in long axis (to exclude non-specific perivascular changes) were recorded for each subject.
RESULTS: There was a significant increase in lesions detected by MRI in SS patients versus controls (p = 0.02) including deep white matter lesions (p = 0.03) and subcortical white matter lesions (p = 0.02). The presence of white matter lesions did not correlate with serum IgG or rheumatoid factor levels, or with presence of anticardiolipin antibodies. No subjects had symptoms or signs of serious neurological disease including multiple sclerosis, and corpus callosal lesions commonly seen in multiple sclerosis were notably absent in this study.
CONCLUSION: Cerebral white matter lesions detected by MRI are more frequent in patients with primary SS than control subjects, yet do not appear to be associated with significant clinical manifestations. Although the pathological nature of these lesions is yet to be defined, their presence should not be over-interpreted.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381047

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

Review 1.  CNS involvement in primary Sjögren's syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach.

Authors:  M Govoni; M Padovan; N Rizzo; F Trotta
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Central nervous system involvement in Sjogren's syndrome.

Authors:  F C Soliotis; C P Mavragani; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

3.  Primary Sjögren's syndrome and risk of ischemic stroke: a nationwide study.

Authors:  Chia-Hung Chiang; Chia-Jen Liu; Ping-Jen Chen; Chin-Chou Huang; Chien-Yi Hsu; Wan-Leong Chan; Po-Hsun Huang; Tzeng-Ji Chen; Shing-Jong Lin; Jaw-Wen Chen; Hsin-Bang Leu
Journal:  Clin Rheumatol       Date:  2014-03-21       Impact factor: 2.980

4.  Intracranial hemodynamic changes in primary Sjögren syndrome: a transcranial Doppler case-control study.

Authors:  Manuela Morreale; Ada Francia; Pasquale Marchione; Federica Manuppella; Patrizia Giacomini
Journal:  Neurol Sci       Date:  2015-04-14       Impact factor: 3.307

Review 5.  Primary Sjögren's syndrome: new clinical and therapeutic concepts.

Authors:  M Ramos-Casals; A G Tzioufas; J Font
Journal:  Ann Rheum Dis       Date:  2004-10-21       Impact factor: 19.103

Review 6.  Sjögren's syndrome: diagnosis and therapeutic challenges in the elderly.

Authors:  Kristine P Ng; David A Isenberg
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

7.  Neurological Complications of Sjögren's Syndrome: Diagnosis and Management.

Authors:  Sara S McCoy; Alan N Baer
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-10-24

8.  Cognition, depression, fatigue, and quality of life in primary Sjögren's syndrome: correlations.

Authors:  Belgin Koçer; Mehmet Engin Tezcan; Hale Zeynep Batur; Şeminur Haznedaroğlu; Berna Göker; Ceyla İrkeç; Rümeysa Çetinkaya
Journal:  Brain Behav       Date:  2016-10-13       Impact factor: 2.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.